Lacosamide
Also known as: Vimpat · Lacosamide UCB · Lacosamide Accord · Lacosamide Adroiq · Lacosamide Oral Solution
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, lacosamide is indicated as monotherapy and adjunctive therapy to treat partial-onset seizures with or without secondary generalisation in adults, adolescents, and children from 4 years of age with epilepsy. In the United States, lacosamide is indicated for the treatment of partial-onset seizures in patients 1 month of age and older, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients 4 years of age and older. The medicine is listed by the cited source as having an approved use for epilepsy.
From: Source: European Medicines Agency (EMA), Lacosamide UCB — EPAR, 20/08/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA), Vimpat — EPAR, 20/08/2026. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 623400 lacosamide
- EMA
- EMEA/H/C/000863, EMEA/H/C/005243, EMEA/H/C/004443, EMEA/H/C/006047
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
FDA (USA) LACOSAMIDE
1 INDICATIONS AND USAGE Lacosamide is indicated for: Treatment of partial-onset seizures in patients 1 month of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older (1.2) 1.1 Partial-Onset Seizures Lacosamide is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Primary Generalized Tonic-Clonic Seizures Lacosamide is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
Data provided by the U.S. Food and Drug Administration.
Document date: 20260611 · Official document →
EMA (EU) Lacosamide UCB
Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Source: European Medicines Agency (EMA), Lacosamide UCB — EPAR, 20/08/2026. © European Medicines Agency.
Document date: 20/08/2026 · Official document →
EMA (EU) Vimpat
Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Source: European Medicines Agency (EMA), Vimpat — EPAR, 20/08/2026. © European Medicines Agency.
Document date: 20/08/2026 · Official document →
Related terms in the cited sources
Has an official indication for
- Epilepsy Condition
In alphabetical order.
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Lacosamide approved for in the European Union?
Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. (Source: European Medicines Agency (EMA), Lacosamide UCB — EPAR, 20/08/2026. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Data provided by the U.S. Food and Drug Administration.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Lacosamide UCB — EPAR, 20/08/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Vimpat — EPAR, 20/08/2026. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.